Over 100 vaccines are developed and tested worldwide (representation)
London:
Positive news about the initial trials of the potential University of Oxford COVID-19 vaccine that has been licensed to AstraZeneca could be announced as early as Thursday, said ITV political editor Robert Peston, citing a source.
The potential vaccine is already undergoing large-scale phase III human trials to assess whether it can protect against COVID-19, but its developers have not yet released phase I results that would show it is safe and whether or not it induces an immune response. .
The vaccine developers said this month that they were encouraged by the immune response they had observed so far and expected to release the phase 1 data by the end of July.
The data should be published by the medical journal The Lancet.
More than 100 vaccines are being developed and tested worldwide to try to stop the COVID-19 pandemic, which has killed hundreds of thousands of people and ravaged the global economy.
AstraZeneca’s experimental vaccine is probably the world‘s first and most advanced candidate for development, said the chief scientist at the World Health Organization in June.
The company has signed agreements with governments around the world to supply the vaccine if it is approved for use.
AstraZeneca shares rose 5% at 2:15 p.m. GMT. There were no immediate company comments on the report.
A spokeswoman for the University of Oxford told Reuters that the team was awaiting confirmation from a scientific journal of the date and time of publication of the data, but gave no further details. “(We) are unable to confirm the date of his release,” she said.
Peston said in a blog post: “I hear there will soon be positive news (maybe tomorrow) about the first trials of the Oxford COVID-19 vaccine which is supported by AstraZeneca.”
American researchers reported on Tuesday that Moderna Inc’s experimental vaccine had shown to be safe and elicited immune responses in 45 healthy volunteers in an early-stage study.
Moderna started its phase II trial in May and plans to start a phase III trial on July 27.
(Reporting by William Schomberg and Kate Kelland; Writing by Alistair Smout; Editing by Keith Weir and Edmund Blair)
(With the exception of the title, this story was not edited by GalacticGaming staff and is published from a syndicated feed.)
